1YG Stock Overview
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.026 |
| 52 Week High | kr0.14 |
| 52 Week Low | kr0.0004 |
| Beta | 0.98 |
| 1 Month Change | 4.84% |
| 3 Month Change | -6.14% |
| 1 Year Change | -81.05% |
| 3 Year Change | -94.57% |
| 5 Year Change | -96.57% |
| Change since IPO | -96.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1YG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.8% | -0.2% | 0.5% |
| 1Y | -81.0% | -22.8% | 1.3% |
Return vs Industry: 1YG underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 1YG underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 1YG volatility | |
|---|---|
| 1YG Average Weekly Movement | 62.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1YG's share price has been volatile over the past 3 months.
Volatility Over Time: 1YG's weekly volatility has decreased from 170% to 62% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 30 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| 1YG fundamental statistics | |
|---|---|
| Market cap | €40.53m |
| Earnings (TTM) | -€8.70m |
| Revenue (TTM) | €2.44m |
16.6x
P/S Ratio-4.7x
P/E RatioIs 1YG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1YG income statement (TTM) | |
|---|---|
| Revenue | kr28.49m |
| Cost of Revenue | kr0 |
| Gross Profit | kr28.49m |
| Other Expenses | kr130.11m |
| Earnings | -kr101.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 100.00% |
| Net Profit Margin | -356.72% |
| Debt/Equity Ratio | 0.1% |
How did 1YG perform over the long term?
See historical performance and comparison